Related Experiment Video
Updated: Aug 26, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
560
lncRNA PVT1: a novel oncogene in multiple cancers
Ruiming Li1, Xia Wang1, Chunming Zhu2
1Department of Urology, Shengjing Hospital of China Medical University, #36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China.
Cellular & Molecular Biology Letters
|October 4, 2022
Summary
Long noncoding RNA plasmacytoma variant translocation 1 (PVT1) is implicated in cancer development, influencing tumor progression, resistance to therapy, and patient prognosis. Understanding PVT1 expression offers new diagnostic and therapeutic strategies for various cancers.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Long noncoding RNAs (lncRNAs) regulate gene expression epigenetically at pre-transcriptional, transcriptional, and post-transcriptional levels.
- The lncRNA plasmacytoma variant translocation 1 (PVT1) has emerged as a significant factor in the development and progression of various cancers.
- PVT1's roles span epigenetic modification, gene regulation, and microRNA sponging, impacting cellular processes relevant to oncogenesis.
Purpose of the Study:
- To comprehensively review the extensive literature on the long noncoding RNA PVT1 in the context of cancer.
- To elucidate the multifaceted roles of PVT1 in tumor onset, proliferation, invasion, epithelial-mesenchymal transition, and apoptosis.
- To summarize PVT1's association with poor prognosis and resistance to radiotherapy and chemotherapy, and to explore novel diagnostic and therapeutic applications.
Main Methods:
- Systematic literature review and analysis of published studies on PVT1 and cancer.
- Compilation and synthesis of data regarding PVT1 expression patterns across diverse cancer types.
- Evaluation of evidence linking PVT1 to key cancer hallmarks and treatment outcomes.
Main Results:
- PVT1 expression is significantly altered in numerous cancers, correlating with tumor initiation and progression.
- PVT1 influences critical cancer processes including proliferation, invasion, epithelial-mesenchymal transition, and apoptosis.
- Elevated PVT1 levels are associated with poor patient prognosis and resistance to common cancer therapies like radiotherapy and chemotherapy.
Conclusions:
- The long noncoding RNA PVT1 is a critical oncogenic factor implicated in multiple facets of cancer development and progression.
- PVT1's dysregulation in various cancers highlights its potential as a biomarker for diagnosis and prognosis.
- Targeting PVT1 presents a promising avenue for developing novel cancer treatment strategies and overcoming therapeutic resistance.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
01:33Cancer-Critical Genes I: Proto-oncogenes
9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
03:18Non-LTR Retrotransposons
11.7K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.7K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.3K
01:06Induced Pluripotent Stem Cells
4.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.3K